Tags

Type your tag names separated by a space and hit enter

Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.

Abstract

Spinocerebellar ataxias (SCAs) are devastating neurodegenerative disorders for which no curative or preventive therapies are available. Deregulation of brain cholesterol metabolism and impaired brain cholesterol turnover have been associated with several neurodegenerative diseases. SCA3 or Machado-Joseph disease (MJD) is the most prevalent ataxia worldwide. We show that cholesterol 24-hydroxylase (CYP46A1), the key enzyme allowing efflux of brain cholesterol and activating brain cholesterol turnover, is decreased in cerebellar extracts from SCA3 patients and SCA3 mice. We investigated whether reinstating CYP46A1 expression would improve the disease phenotype of SCA3 mouse models. We show that administration of adeno-associated viral vectors encoding CYP46A1 to a lentiviral-based SCA3 mouse model reduces mutant ataxin-3 accumulation, which is a hallmark of SCA3, and preserves neuronal markers. In a transgenic SCA3 model with a severe motor phenotype we confirm that cerebellar delivery of AAVrh10-CYP46A1 is strongly neuroprotective in adult mice with established pathology. CYP46A1 significantly decreases ataxin-3 protein aggregation, alleviates motor impairments and improves SCA3-associated neuropathology. In particular, improvement in Purkinje cell number and reduction of cerebellar atrophy are observed in AAVrh10-CYP46A1-treated mice. Conversely, we show that knocking-down CYP46A1 in normal mouse brain impairs cholesterol metabolism, induces motor deficits and produces strong neurodegeneration with impairment of the endosomal-lysosomal pathway, a phenotype closely resembling that of SCA3. Remarkably, we demonstrate for the first time both in vitro, in a SCA3 cellular model, and in vivo, in mouse brain, that CYP46A1 activates autophagy, which is impaired in SCA3, leading to decreased mutant ataxin-3 deposition. More broadly, we show that the beneficial effect of CYP46A1 is also observed with mutant ataxin-2 aggregates. Altogether, our results confirm a pivotal role for CYP46A1 and brain cholesterol metabolism in neuronal function, pointing to a key contribution of the neuronal cholesterol pathway in mechanisms mediating clearance of aggregate-prone proteins. This study identifies CYP46A1 as a relevant therapeutic target not only for SCA3 but also for other SCAs.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. Centre for Biomedical Research, University of Algarve, Faro, Portugal. Algarve Biomedical Center, University of Algarve, Faro, Portugal. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

    ,

    Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

    ,

    Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. Centre for Biomedical Research, University of Algarve, Faro, Portugal.

    ,

    INSERM, Saint-Antoine Research Center, Sorbonne Université, Faculté de Médecine, AP-HP, Hôpital Saint Antoine, Département PM2, Paris, France.

    ,

    Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

    ,

    INSERM, Saint-Antoine Research Center, Sorbonne Université, Faculté de Médecine, AP-HP, Hôpital Saint Antoine, Département PM2, Paris, France.

    ,

    Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. Centre for Biomedical Research, University of Algarve, Faro, Portugal. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

    ,

    Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. Centre for Biomedical Research, University of Algarve, Faro, Portugal.

    ,

    Institut du Cerveau et de la Moelle épinière, ICM, INSERM U1127, CNRS UMR7225, Sorbonne Université, Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013, Paris, France.

    ,

    Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

    ,

    Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. luispa@cnc.uc.pt. Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal. luispa@cnc.uc.pt.

    ,

    INSERM U1169 92265 Fontenay aux Roses and Université Paris-Sud, Université Paris Saclay, 91400, Orsay, France. nathalie.cartier@inserm.fr. INSERM U1127, Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, 47 bd de l'hôpital, 75013, Paris, France. nathalie.cartier@inserm.fr.

    Brainvectis, Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, 47 boulevard de l'Hôpital Paris, 75646, Paris, CEDEX 13, France. sandro.alves@brainvectis.com.

    Source

    Acta neuropathologica : 2019 Jun 14 pg

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    31197505

    Citation

    Nóbrega, Clévio, et al. "Restoring Brain Cholesterol Turnover Improves Autophagy and Has Therapeutic Potential in Mouse Models of Spinocerebellar Ataxia." Acta Neuropathologica, 2019.
    Nóbrega C, Mendonça L, Marcelo A, et al. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol. 2019.
    Nóbrega, C., Mendonça, L., Marcelo, A., Lamazière, A., Tomé, S., Despres, G., ... Alves, S. (2019). Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathologica, doi:10.1007/s00401-019-02019-7.
    Nóbrega C, et al. Restoring Brain Cholesterol Turnover Improves Autophagy and Has Therapeutic Potential in Mouse Models of Spinocerebellar Ataxia. Acta Neuropathol. 2019 Jun 14; PubMed PMID: 31197505.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. AU - Nóbrega,Clévio, AU - Mendonça,Liliana, AU - Marcelo,Adriana, AU - Lamazière,Antonin, AU - Tomé,Sandra, AU - Despres,Gaetan, AU - Matos,Carlos A, AU - Mechmet,Fatich, AU - Langui,Dominique, AU - den Dunnen,Wilfred, AU - de Almeida,Luis Pereira, AU - Cartier,Nathalie, AU - Alves,Sandro, Y1 - 2019/06/14/ PY - 2018/10/02/received PY - 2019/04/20/accepted PY - 2019/04/04/revised PY - 2019/6/15/entrez KW - 24-Cholesterol hydroxylase KW - Ataxia KW - Autophagy KW - Cholesterol metabolism KW - SCA animal models KW - SCA patients JF - Acta neuropathologica JO - Acta Neuropathol. N2 - Spinocerebellar ataxias (SCAs) are devastating neurodegenerative disorders for which no curative or preventive therapies are available. Deregulation of brain cholesterol metabolism and impaired brain cholesterol turnover have been associated with several neurodegenerative diseases. SCA3 or Machado-Joseph disease (MJD) is the most prevalent ataxia worldwide. We show that cholesterol 24-hydroxylase (CYP46A1), the key enzyme allowing efflux of brain cholesterol and activating brain cholesterol turnover, is decreased in cerebellar extracts from SCA3 patients and SCA3 mice. We investigated whether reinstating CYP46A1 expression would improve the disease phenotype of SCA3 mouse models. We show that administration of adeno-associated viral vectors encoding CYP46A1 to a lentiviral-based SCA3 mouse model reduces mutant ataxin-3 accumulation, which is a hallmark of SCA3, and preserves neuronal markers. In a transgenic SCA3 model with a severe motor phenotype we confirm that cerebellar delivery of AAVrh10-CYP46A1 is strongly neuroprotective in adult mice with established pathology. CYP46A1 significantly decreases ataxin-3 protein aggregation, alleviates motor impairments and improves SCA3-associated neuropathology. In particular, improvement in Purkinje cell number and reduction of cerebellar atrophy are observed in AAVrh10-CYP46A1-treated mice. Conversely, we show that knocking-down CYP46A1 in normal mouse brain impairs cholesterol metabolism, induces motor deficits and produces strong neurodegeneration with impairment of the endosomal-lysosomal pathway, a phenotype closely resembling that of SCA3. Remarkably, we demonstrate for the first time both in vitro, in a SCA3 cellular model, and in vivo, in mouse brain, that CYP46A1 activates autophagy, which is impaired in SCA3, leading to decreased mutant ataxin-3 deposition. More broadly, we show that the beneficial effect of CYP46A1 is also observed with mutant ataxin-2 aggregates. Altogether, our results confirm a pivotal role for CYP46A1 and brain cholesterol metabolism in neuronal function, pointing to a key contribution of the neuronal cholesterol pathway in mechanisms mediating clearance of aggregate-prone proteins. This study identifies CYP46A1 as a relevant therapeutic target not only for SCA3 but also for other SCAs. SN - 1432-0533 UR - https://www.unboundmedicine.com/medline/citation/31197505/Restoring_brain_cholesterol_turnover_improves_autophagy_and_has_therapeutic_potential_in_mouse_models_of_spinocerebellar_ataxia L2 - https://dx.doi.org/10.1007/s00401-019-02019-7 DB - PRIME DP - Unbound Medicine ER -